50% recruitment reached in VF00102 Clinical Trial
Filed with ASX · · 1 page · English
InVert Graphite Limited on 6ix
Story so far
Earlier from InVert Graphite
- Appendix 4C for the September Quarter
- Shareholder communication - clinical trial update
- Appendix 4E and Full Year Statutory Accounts
- Appendix 4C - quarterly
- Appointment of Dr. Rosalind Wilson as CEO
Later from InVert Graphite
- Factor receives $3.1M R&D tax rebate
- Shareholder Update
- Appendix 4C - December 2017 Quarter
- Appendix 4E Preliminary Final Report
- Rights Issue Entitlement Offer Information Booklet
Follow InVert Graphite into a list and get an email when it puts out news.
Follow InVert Graphite